The primary tumor site distribution was nearly significant, with a higher proportion of HER2-patients having bladder tumors (64.56%) compared to HER2+ patients (77.85%) and a lower proportion of HER2-patients having ureteral (24.05%) and renal pelvis (11.39%) tumors compared to HER2+ patients (12.66% and 9.49%, respectively) (p = 0.061). This evidence concerns the gene ERBB2 and urinary bladder neoplasm.